Wai Yuen Tong Medicine Holdings Limited (HKG:0897)

Revenue by Segment

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Chinese Pharmaceutical	607.17M	651.71M	690.60M	636.43M	512.61M
Western Pharmaceutical	74.03M	91.57M	90.21M	83.13M	43.09M
Property Investment	6.47M	9.17M	18.79M	21.67M	20.18M
Eliminations	-4.22M	-7.15M	-15.72M	-17.63M	-14.94M
Management and Sale of Properties in Agricultural Produce Exchange Markets	-	-	-	-	830.47M
Total	683.44M	745.30M	783.88M	723.60M	1.39B

Revenue by Geography

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Hong Kong	523.99M	557.05M	580.81M	534.76M	417.99M
Mainland China	96.10M	124.56M	114.95M	130.92M	929.12M
Macau	59.06M	59.78M	83.72M	54.08M	40.55M
Others	4.30M	3.92M	4.41M	3.84M	3.74M
Total	683.44M	745.30M	783.88M	723.60M	1.39B

Data Source: S&P Global Market Intelligence Last updated: Jul 24, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 30, 2026

Data Sources Report a data error